{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-008977","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.213756+00:00","generated_at":"2026-06-25T14:48:19.833354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biostage Q1 net loss widens to $2.2M; settles lawsuit, raises $5.1M placement","bullets":["Q1 net loss of $2.2M ($0.20 per share) vs $0.9M loss ($0.09) in Q1 2021; G&A up $1.4M on legal costs.","Raised $5.1M via private placement on May 12, 2022 to fund clinical development of BEI.","Settled wrongful death lawsuit on April 27, 2022; total estimated costs $6.0M, $5.5M unpaid; HBIO to pay $4.0M.","Cash on hand $0.7M at March 31, 2022; after placement, cash expected to fund operations through Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-008977","json":"https://secwatch.observer/filing/0001558370-22-008977.json","markdown":"https://secwatch.observer/filing/0001558370-22-008977.md","text":"https://secwatch.observer/filing/0001558370-22-008977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000155837022008977/0001558370-22-008977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000155837022008977/tmb-20220516x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T14:48:19.833354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}